Avinger Inc. (NASDAQ:AVGR) traded down 4.7% on Friday . The stock traded as low as $4.37 and last traded at $4.47, with a volume of 370,509 shares. The stock had previously closed at $4.69.

Several equities research analysts recently weighed in on the stock. BTIG Research reaffirmed a “buy” rating and set a $6.00 target price (down from $18.00) on shares of Avinger in a research note on Monday, August 15th. Zacks Investment Research raised shares of Avinger from a “sell” rating to a “hold” rating in a research note on Friday, July 1st. Finally, Canaccord Genuity reaffirmed a “buy” rating on shares of Avinger in a research note on Tuesday, July 12th. Two equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. The company presently has an average rating of “Buy” and an average target price of $15.75.

The company has a 50-day moving average of $6.38 and a 200-day moving average of $10.61. The stock’s market capitalization is $55.09 million.

Avinger (NASDAQ:AVGR) last released its quarterly earnings results on Monday, August 1st. The medical device company reported ($1.06) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($1.15) by $0.09. The firm had revenue of $4.70 million for the quarter, compared to analyst estimates of $3.05 million. On average, equities analysts forecast that Avinger Inc. will post ($4.16) earnings per share for the current fiscal year.

In other news, CEO Jeffrey M. Soinski purchased 57,100 shares of the firm’s stock in a transaction on Tuesday, August 16th. The shares were bought at an average cost of $3.50 per share, with a total value of $199,850.00. Following the purchase, the chief executive officer now directly owns 59,345 shares of the company’s stock, valued at $207,707.50. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Avinger, Inc is a commercial-stage medical device company. The Company designs, manufactures and sells image-guided, catheter-based systems that are used by physicians to treat patients with peripheral arterial disease (PAD). The Company focuses on introducing products based on its lumivascular platform, which is an intravascular image-guided system.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.